CENTRAL, PERIPHERAL AND HEMODYNAMIC EFFECTS OF NANOFORMULATED ANANDAMIDE DURING HYPERTENSION

MARTÍN GIMÉNEZ VIRNA; MOCAYAR MARÓN FERES; GARCÍA MENENDEZ SEBASTIÁN; GUEVARA MANUEL ALEJANDRO; MAZZEI LUCIANA; FUENTES L; KASSUHA DIEGO; YUNES ROBERTO; MANUCHA WALTER

San Luis

Jornada; XXXVII Reunión Científica Anual Sociedad de Biología de Cuyo; 2019

Sociedad de Biología de Cuyo

Hypertensive lesions - dependent on inflammatory processes - would cause alterations at the central nervous system level withperipheral and hemodynamic consequences. Anandamide (AEA), an endocannabinoid, protects neurons from inflammatory damage.However, the administration of free AEA may produce central side effects but its controlled release by nanoformulations would reduceor eliminate them. We evaluated possible effects of nanoformulated AEA on blood pressure, central and systemic inflammatorymarkers and behavioral alterations in SHR and WKY. We used male rats of 250-300 g (N = 7 per group) normotensive (WKY) andhypertensive (SHR) with and without treatment with nanoformulated AEA at a weekly dose of 5 mg/kg IP, for four weeks. Wedetermined systolic blood pressure, expression of WT-1, Hsp-70, AT1 and iNOS in brain tissue, behavior, and blood levels ofultrasensitive PCR, IL-1, IL-6, TNF-alpha, Hsp-70, NADPH oxidase and nitrites. We use ANOVA II and the Bonferroni post-test (p